CMC
ACHAT TOTAL: 9 620 titres (~604 467,80 $ US)
- Insiders
- McPherson John R, MATT PETER R
- Total bought
- $604,468
- Total sold
- —
- Last activity
- 2026-08-13
- Last synced
-
2026-08-21 23:36:53
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-08-16
CMC presents a genuine event-driven catalyst — insider cluster buys, a $600M buyback expansion, and an ambitious $1.8B EBITDA target signal management conviction in a near-term turnaround, supported by institutional…
The first sentence of the analysis written for CMC on 2026-08-16 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 | 2021-08-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 15.6% | 17.1% | 20.6% | 20.8% | 16.4% | |
| Ebit Margin | 2.0% | 8.6% | 13.2% | 17.6% | 8.7% | |
| Ebitda Margin | 5.6% | 12.2% | 15.7% | 19.5% | 11.2% | |
| Operating Profit Margin | 6.7% | 8.8% | 13.3% | 14.7% | 8.9% | |
| Pretax Profit Margin | 1.4% | 8.0% | 12.8% | 17.0% | 7.9% | |
| Continuous Operations Profit Margin | 1.1% | 6.1% | 9.8% | 13.7% | 6.1% | |
| Net Profit Margin | 1.1% | 6.1% | 9.8% | 13.7% | 6.1% | |
| Bottom Line Profit Margin | 1.1% | 6.1% | 9.8% | 13.7% | 6.1% | |
| Current Ratio | 2.776 | 3.944 | 3.727 | 2.536 | 2.791 | |
| Quick Ratio | 2.034 | 2.780 | 2.499 | 1.674 | 1.837 | |
| Solvency Ratio | 0.124 | 0.304 | 0.428 | 0.472 | 0.248 | |
| Cash Ratio | 0.829 | 1.028 | 0.702 | 0.496 | 0.508 | |
| Price To Earnings Ratio | 76.893 | 12.790 | 7.669 | 4.015 | 9.510 | |
| Price To Earnings Growth Ratio | -0.937 | -0.298 | -0.281 | 0.021 | 0.207 | |
| Forward Price To Earnings Growth Ratio | -0.937 | -0.298 | -0.281 | 0.021 | 0.207 | |
| Price To Earnings Diluted Ratio | 77.932 | 12.944 | 7.764 | 4.071 | 9.651 | |
| Price To Earnings Diluted Growth Ratio | -0.949 | -0.302 | -0.286 | 0.021 | 0.211 | |
| Price To Book Ratio | 1.554 | 1.444 | 1.599 | 1.487 | 1.711 | |
| Price To Sales Ratio | 0.836 | 0.783 | 0.749 | 0.548 | 0.583 | |
| Price To Free Cash Flow Ratio | 20.869 | 10.789 | 8.937 | 19.525 | 88.592 | |
| Price To Operating Cash Flow Ratio | 9.113 | 6.900 | 4.903 | 6.979 | 17.181 | |
| Debt To Assets Ratio | 0.189 | 0.174 | 0.174 | 0.241 | 0.231 | |
| Debt To Equity Ratio | 0.323 | 0.277 | 0.280 | 0.457 | 0.466 | |
| Debt To Capital Ratio | 0.244 | 0.217 | 0.219 | 0.314 | 0.318 | |
| Long Term Debt To Capital Ratio | 0.238 | 0.211 | 0.213 | 0.253 | 0.307 | |
| Financial Leverage Ratio | 1.710 | 1.586 | 1.611 | 1.898 | 2.021 | |
| Working Capital Turnover Ratio | 3.323 | 3.331 | 4.014 | 4.641 | 4.173 | |
| Operating Cash Flow Ratio | 0.568 | 1.078 | 1.593 | 0.516 | 0.233 | |
| Operating Cash Flow Sales Ratio | 0.092 | 0.114 | 0.153 | 0.079 | 0.034 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.437 | 0.640 | 0.549 | 0.357 | 0.194 | |
| Debt Service Coverage Ratio | 4.634 | 9.388 | 13.873 | 3.283 | 5.951 | |
| Interest Coverage Ratio | 11.427 | 14.482 | 29.117 | 25.862 | 11.574 | |
| Short Term Operating Cash Flow Coverage Ratio | 16.146 | 23.197 | 33.177 | 1.801 | 4.203 | |
| Operating Cash Flow Coverage Ratio | 0.528 | 0.756 | 1.164 | 0.466 | 0.214 | |
| Capital Expenditure Coverage Ratio | 1.775 | 2.775 | 2.216 | 1.556 | 1.241 | |
| Dividend Paid And Capex Coverage Ratio | 1.477 | 2.232 | 1.972 | 1.353 | 0.944 | |
| Dividend Payout Ratio | 0.962 | 0.162 | 0.087 | 0.056 | 0.140 | |
| Enterprise Value Multiple | 15.555 | 6.785 | 5.180 | 3.284 | 5.968 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 15.7% | ▼-1.5% | ▼-2.5% |
| Ebit Margin | 2.0% | ▼-6.7% | ▼-8.1% |
| Ebitda Margin | 5.6% | ▼-6.5% | ▼-7.2% |
| Operating Profit Margin | 6.7% | ▼-2.1% | ▼-3.8% |
| Pretax Profit Margin | 1.4% | ▼-6.6% | ▼-8.0% |
| Continuous Operations Profit Margin | 1.1% | ▼-5.0% | ▼-6.3% |
| Net Profit Margin | 1.1% | ▼-5.0% | ▼-6.3% |
| Bottom Line Profit Margin | 1.1% | ▼-5.0% | ▼-6.3% |
| Current Ratio | 2.776 | ▼-1.168 | ▼-0.379 |
| Quick Ratio | 2.034 | ▼-0.746 | ▼-0.131 |
| Solvency Ratio | 0.124 | ▼-0.180 | ▼-0.191 |
| Cash Ratio | 0.829 | ▼-0.199 | ▲0.116 |
| Price To Earnings Ratio | 76.893 | ▲64.103 | ▲54.718 |
| Price To Earnings Growth Ratio | -0.937 | ▼-0.639 | ▼-0.679 |
| Forward Price To Earnings Growth Ratio | -0.937 | ▼-0.639 | ▼-0.679 |
| Price To Earnings Diluted Ratio | 77.932 | ▲64.988 | ▲55.460 |
| Price To Earnings Diluted Growth Ratio | -0.949 | ▼-0.647 | ▼-0.688 |
| Price To Book Ratio | 1.554 | ▲0.110 | ▼-0.005 |
| Price To Sales Ratio | 0.836 | ▲0.052 | ▲0.136 |
| Price To Free Cash Flow Ratio | 20.869 | ▲10.081 | ▼-8.873 |
| Price To Operating Cash Flow Ratio | 9.113 | ▲2.213 | ▲0.098 |
| Debt To Assets Ratio | 0.189 | ▲0.014 | ▼-0.013 |
| Debt To Equity Ratio | 0.323 | ▲0.046 | ▼-0.038 |
| Debt To Capital Ratio | 0.244 | ▲0.027 | ▼-0.018 |
| Long Term Debt To Capital Ratio | 0.238 | ▲0.027 | ▼-0.006 |
| Financial Leverage Ratio | 1.710 | ▲0.125 | ▼-0.055 |
| Working Capital Turnover Ratio | 3.323 | ▼-0.009 | ▼-0.574 |
| Operating Cash Flow Ratio | 0.568 | ▼-0.510 | ▼-0.230 |
| Operating Cash Flow Sales Ratio | 0.092 | ▼-0.022 | ▼-0.002 |
| Free Cash Flow Operating Cash Flow Ratio | 0.437 | ▼-0.203 | ▲0.001 |
| Debt Service Coverage Ratio | 4.634 | ▼-4.755 | ▼-2.792 |
| Interest Coverage Ratio | 11.427 | ▼-3.055 | ▼-7.065 |
| Short Term Operating Cash Flow Coverage Ratio | 16.145 | ▼-7.051 | ▲0.441 |
| Operating Cash Flow Coverage Ratio | 0.528 | ▼-0.228 | ▼-0.098 |
| Capital Expenditure Coverage Ratio | 1.775 | ▼-0.999 | ▼-0.137 |
| Dividend Paid And Capex Coverage Ratio | 1.477 | ▼-0.755 | ▼-0.119 |
| Dividend Payout Ratio | 0.962 | ▲0.799 | ▲0.680 |
| Enterprise Value Multiple | 15.555 | ▲8.771 | ▲8.201 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $6.52B | $6.21B | $6.59B | $4.89B | $3.93B | |
| Enterprise value | $6.83B | $6.54B | $7.15B | $5.72B | $4.50B | |
| EV / Sales | 0.88x | 0.82x | 0.81x | 0.64x | 0.67x | |
| EV / Op. cash flow | 9.55x | 7.27x | 5.32x | 8.16x | 19.68x | |
| EV / Free cash flow | 21.86x | 11.37x | 9.70x | 22.84x | 101.50x | |
| EV / EBITDA | 15.55x | 6.79x | 5.18x | 3.28x | 5.97x | |
| Net debt / EBITDA | 0.71x | 0.34x | 0.41x | 0.48x | 0.76x | |
| Current ratio | 2.78x | 3.94x | 3.73x | 2.54x | 2.79x | |
| Income quality | 8.45x | 1.85x | 1.56x | 0.57x | 0.55x | |
| Graham number | $25 | $59 | $76 | $79 | $38 | |
| Graham net-net | -$5 | -$3 | -$4 | -$6 | -$5 | |
| Tax burden | 78.7% | 76.4% | 76.6% | 80.3% | 77.3% | |
| Interest burden | 70.3% | 93.0% | 96.5% | 96.8% | 91.1% | |
| Working capital | $2.24B | $2.46B | $2.30B | $2.08B | $1.76B | |
| Invested capital | $5.58B | $5.66B | $5.35B | $4.50B | $3.40B | |
| Return on assets | 1.2% | 7.1% | 12.9% | 19.5% | 8.9% | |
| Operating ROA | 7.4% | 10.3% | 18.1% | 24.1% | 13.8% | |
| Return on tangible assets | 1.3% | 7.8% | 14.3% | 21.2% | 9.0% | |
| Return on equity | 2.0% | 11.3% | 20.9% | 37.0% | 18.0% | |
| Return on invested capital | 6.9% | 8.8% | 15.3% | 20.0% | 12.5% | |
| Return on capital employed | 8.8% | 11.6% | 20.2% | 26.9% | 16.4% | |
| Earnings yield | 1.3% | 7.8% | 13.0% | 24.9% | 10.5% | |
| Free cash flow yield | 4.8% | 9.3% | 11.2% | 5.1% | 1.1% | |
| Capex / Op. cash flow | 56.3% | 36.0% | 45.1% | 64.3% | 80.6% | |
| Capex / Depreciation | 140.9% | 115.7% | 277.2% | 257.1% | 109.9% | |
| Capex / Sales | 5.2% | 4.1% | 6.9% | 5.0% | 2.7% | |
| SG&A / Sales | 9.0% | 8.4% | 7.3% | 6.1% | 7.5% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.5% | 0.6% | 0.7% | 0.5% | 0.6% | |
| Intangibles / Total assets | 8.3% | 9.1% | 9.7% | 8.1% | 1.6% | |
| Days sales outstanding | 56d | 53d | 51d | 56d | 60d | |
| Days payables outstanding | 20d | 19d | 19d | 22d | 29d | |
| Operating cycle | 108d | 107d | 106d | 116d | 121d | |
| Cash conversion cycle | 88d | 88d | 87d | 94d | 91d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-18 Commercial Metals Company: Working On Its Foundation Commercial Metals Company is executing a strategy focused on higher-margin, less capital-intensive operations following $2.5 billion in transformative M&A. Commercial Metals targets $1.65–$1.80 billion core EBITDA and $11B revenue by 2029, aiming to nearly double free cash flow per share. Leverage remains in the low 2s as Commercial Metals prioritizes EBITDA growth and shareholder returns via increased buybacks over rapid debt reduction.
- 2026-08-11 AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics
- 2026-08-11 Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological
- 2026-08-09 Amundi Purchases 11,065 Shares of Commercial Metals Company $CMC Amundi lifted its holdings in Commercial Metals Company (NYSE: CMC) by 118.0% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 20,443 shares of the basic materials company''s stock after purchasing an additional 11,065 shares during the quarter. Amundi''s holdings in Commercial
- 2026-08-08 Commercial Metals Company (CMC) Analyst/Investor Day Transcript Commercial Metals Company (CMC) Analyst/Investor Day Transcript
- 2026-08-05 Commercial Metals Targets $1.8B EBITDA, Expands Construction Solutions Strategy Commercial Metals NYSE: CMC used its 2026 Investor Day to outline a strategy centered on expanding its early-stage construction offerings, improving operating performance and generating higher cash flow and returns by fiscal 2029.
- 2026-08-05 CMC Highlights Position as a Leading, Early-Stage Construction Solutions Provider and Unveils Long-Term Financial Targets at 2026 Investor Day IRVING, Texas, Aug. 5, 2026 /PRNewswire/ -- CMC (NYSE: CMC) (the "Company") today will host its 2026 Investor Day in New York City, where members of the Company''s leadership team will outline CMC''s strategic vision, growth opportunities, capital allocation framework, and long-term financial targets. "Over the last several years, we have taken deliberate steps to transform CMC into an industry-leading provider of solutions across the early-stage construction ecosystem.
- 2026-08-05 CMC Announces $600 Million Increase in Share Repurchase Program Authorization IRVING, Texas, Aug. 5, 2026 /PRNewswire/ -- CMC (NYSE: CMC) (the "Company" or "CMC") today announced that its Board of Directors has authorized a $600.0 million increase in the Company''s existing common stock repurchase program, bringing the total current capacity of the program to approximately $717.0 million. Approximately $733.0 million of the Company''s common stock has been repurchased under the existing program since its authorization in October 2021.
- 2026-08-04 Commercial Metals Company (NYSE:CMC) Given Consensus Rating of “Moderate Buy” by Brokerages Commercial Metals Company (NYSE: CMC - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the fifteen research firms that are presently covering the stock, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong
- 2026-08-03 Achieve Life Sciences Appoints Ronald Dadino and Gloria Cosgrove to Lead CMC, Supply Chain, and Quality SEATTLE and VANCOUVER, British Columbia, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced the appointments of Ronald Dadino as Senior Vice President, Chemistry, Manufacturing and Controls (CMC) and Supply Chain, and Gloria Cosgrove as Senior Vice President, Quality. Both executives bring decades of leadership across pharmaceutical manufacturing, supply chain, and quality.